BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26350112)

  • 1. Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE).
    Kuemmel A; Simon P; Breitkreuz A; Röhlig J; Luxemburger U; Elsäßer A; Schmidt LH; Sebastian M; Sahin U; Türeci Ö; Buhl R
    Lung Cancer; 2015 Nov; 90(2):334-41. PubMed ID: 26350112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.
    Komatsu N; Jackson HM; Chan KF; Oveissi S; Cebon J; Itoh K; Chen W
    Mol Immunol; 2013 Jul; 54(3-4):465-71. PubMed ID: 23454162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of preexisting humoral immunity specific for two cancer-testis antigens overexpressed at the mRNA level in non-small cell lung cancer.
    Watanabe Y; LePage S; Elliott M; Secrist H; Tanaka T; Kawahara M; Matsumura A; Hosoe S; Ogawara M; Okada M; Repasky B; Sleath P; Wang T; Henderson R
    Cancer Immun; 2006 Feb; 6():3. PubMed ID: 16468707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Transmembrane Phosphatase with Tensin homology (TPTE) in prostate cancer is clinically significant, suggesting its potential as a valuable biomarker.
    Zainodini N; Abolhasani M; Mohsenzadegan M; Farajollahi MM; Rismani E
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):165. PubMed ID: 38546751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.
    Kawabata R; Wada H; Isobe M; Saika T; Sato S; Uenaka A; Miyata H; Yasuda T; Doki Y; Noguchi Y; Kumon H; Tsuji K; Iwatsuki K; Shiku H; Ritter G; Murphy R; Hoffman E; Old LJ; Monden M; Nakayama E
    Int J Cancer; 2007 May; 120(10):2178-84. PubMed ID: 17278093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NY-ESO-1 protein expression and humoral immune responses in prostate cancer.
    Fosså A; Berner A; Fosså SD; Hernes E; Gaudernack G; Smeland EB
    Prostate; 2004 Jun; 59(4):440-7. PubMed ID: 15065093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against the cancer-testis antigen CTSP-1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrence.
    Parmigiani RB; Bettoni F; Grosso DM; Lopes A; Cunha IW; Soares FA; Carvalho AL; Fonseca F; Camargo AA
    Int J Cancer; 2008 May; 122(10):2385-90. PubMed ID: 18214856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
    Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
    PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer.
    Djureinovic D; Dodig-Crnković T; Hellström C; Holgersson G; Bergqvist M; Mattsson JSM; Pontén F; Ståhle E; Schwenk JM; Micke P
    Lung Cancer; 2018 Nov; 125():157-163. PubMed ID: 30429015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous remission of a non-small cell lung cancer possibly caused by anti-NY-ESO-1 immunity.
    Nakamura Y; Noguchi Y; Satoh E; Uenaka A; Sato S; Kitazaki T; Kanda T; Soda H; Nakayama E; Kohno S
    Lung Cancer; 2009 Jul; 65(1):119-22. PubMed ID: 19193472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
    Kawada J; Wada H; Isobe M; Gnjatic S; Nishikawa H; Jungbluth AA; Okazaki N; Uenaka A; Nakamura Y; Fujiwara S; Mizuno N; Saika T; Ritter E; Yamasaki M; Miyata H; Ritter G; Murphy R; Venhaus R; Pan L; Old LJ; Doki Y; Nakayama E
    Int J Cancer; 2012 Feb; 130(3):584-92. PubMed ID: 21413013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance.
    Yoshida N; Abe H; Ohkuri T; Wakita D; Sato M; Noguchi D; Miyamoto M; Morikawa T; Kondo S; Ikeda H; Nishimura T
    Int J Oncol; 2006 May; 28(5):1089-98. PubMed ID: 16596224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
    Grah J; Samija M; Juretić A; Sarcević B; Sobat H
    Coll Antropol; 2008 Sep; 32(3):731-6. PubMed ID: 18982744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients.
    Dong XY; Su YR; Qian XP; Yang XA; Pang XW; Wu HY; Chen WF
    Br J Cancer; 2003 Jul; 89(2):291-7. PubMed ID: 12865919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.
    Ayyoub M; Souleimanian NE; Godefroy E; Scotto L; Hesdorffer CS; Old LJ; Valmori D
    Clin Immunol; 2006; 118(2-3):188-94. PubMed ID: 16368270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
    Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
    Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum antibodies to retinal antigens in lung cancer and sarcoidosis.
    Jankowska R; Witkowska D; Porebska I; Kuropatwa M; Kurowska E; Gorczyca WA
    Pathobiology; 2004; 71(6):323-8. PubMed ID: 15627843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer.
    Wang Y; Wu XJ; Zhao AL; Yuan YH; Chen YT; Jungbluth AA; Gnjatic S; Santiago D; Ritter G; Chen WF; Old LJ; Ji JF
    Cancer Immun; 2004 Nov; 4():11. PubMed ID: 15516106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
    Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer.
    Brichory F; Beer D; Le Naour F; Giordano T; Hanash S
    Cancer Res; 2001 Nov; 61(21):7908-12. PubMed ID: 11691811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.